The 5-Year Clinical Outcomes After a Randomized Comparison of Sirolimus-Eluting Versus Bare-Metal Stent Implantation in Patients With ST-Segment Elevation Myocardial Infarction

Journal of the American College of Cardiology

Volumn 54, Issue 20, 2009, Pages 1900-1901

  Tebaldi, Matteo ^a   Arcozzi, Chiara ^a   Campo, Gianluca ^a   Percoco, Gianfranco ^a   Ferrari, Roberto ^a   Valgimigli, Marco ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; RAPAMYCIN; TIROFIBAN;

BARE METAL STENT; DRUG ELUTING STENT; HEART INFARCTION; HUMAN; INTERMETHOD COMPARISON; LETTER; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; REVASCULARIZATION; ST SEGMENT ELEVATION; STENT THROMBOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; DRUG-ELUTING STENTS; FOLLOW-UP STUDIES; HUMANS; MYOCARDIAL INFARCTION; PROSTHESIS IMPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS;

EID: 70350537396     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.08.009     Document Type: Letter

References (8)

1. Pfisterer M., Brunner-La Rocca H.P., Buser P.T., et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 48 (2006) 2584-2591
2. Spertus J.A., Kettelkamp R., Vance C., et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 113 (2006) 2803-2809
3. Steg P.G., Fox K.A., Eagle K.A., et al. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. Eur Heart J 30 (2009) 321-329
4. Valgimigli M., Percoco G., Cicchitelli G., et al. High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study-protocol design and demography of the first 100 patients. Cardiovasc Drugs Ther 18 (2004) 225-230
5. Valgimigli M., Percoco G., Malagutti P., et al. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA 293 (2005) 2109-2117
6. Valgimigli M., Campo G., Arcozzi C., et al. Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa inhibitor infusion in patients with myocardial infarction: results from the STRATEGY study. J Am Coll Cardiol 50 (2007) 138-145
7. Synergy between stent and drugs to avoid ischemic recurrences after percutaneous coronary intervention. The PRODIGY trial. http://clinicaltrials.gov/ct2/show/NCT00611286?term=prodigy&rank=3 Accessed August 6, 2009
8. Daemen J., Tanimoto S., Garcia-Garcia H.M., et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 99 (2007) 1027-1032